Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels.
Goto K, Nagamatsu H, Teishima J, Kohada Y, Fujii S, Kurimura Y, Mita K, Shigeta M, Maruyama S, Inoue Y, Nakahara M, Matsubara A. Goto K, et al. Among authors: maruyama s. Mol Clin Oncol. 2017 May;6(5):748-752. doi: 10.3892/mco.2017.1223. Epub 2017 Apr 10. Mol Clin Oncol. 2017. PMID: 28515927 Free PMC article.
The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Teishima J, Kobatake K, Shinmei S, Inoue S, Hayashi T, Ohara S, Mita K, Hasegawa Y, Maruyama S, Kajiwara M, Shigeta M, Mochizuki H, Moriyama H, Fujiwara S, Matsubara A. Teishima J, et al. Among authors: maruyama s. Urol Oncol. 2017 Nov;35(11):662.e1-662.e7. doi: 10.1016/j.urolonc.2017.07.008. Epub 2017 Aug 1. Urol Oncol. 2017. PMID: 28778585
Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
Teishima J, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A. Teishima J, et al. Among authors: maruyama s. Can Urol Assoc J. 2020 Nov;14(11):E582-E587. doi: 10.5489/cuaj.6413. Can Urol Assoc J. 2020. PMID: 32520703 Free PMC article.
Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
Teishima J, Goto K, Sekino Y, Mita K, Hayashi T, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Kadonishi Y, Fujiwara S, Kobayashi K, Asano K, Hinata N. Teishima J, et al. Among authors: maruyama s. Int Urol Nephrol. 2022 Jun;54(6):1225-1232. doi: 10.1007/s11255-022-03157-w. Epub 2022 Mar 22. Int Urol Nephrol. 2022. PMID: 35314918
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K, Teishima J, Goto K, Aoki G, Sekino Y, Hayashi T, Hasegawa Y, Mita K, Kato M, Kajiwara M, Shigeta M, Maruyama S, Kadonishi Y, Fujiwara S, Hinata N. Yukihiro K, et al. Among authors: maruyama s. Urol Oncol. 2022 Oct;40(10):455.e11-455.e18. doi: 10.1016/j.urolonc.2022.06.016. Epub 2022 Jul 16. Urol Oncol. 2022. PMID: 35851184
Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
Takemoto K, Sekino Y, Kitano H, Ikeda K, Goto K, Hieda K, Hayashi T, Hasegawa Y, Kato M, Kadonishi Y, Kajiwara M, Teishima J, Mita K, Maruyama S, Shigeta M, Hinata N. Takemoto K, et al. Among authors: maruyama s. Int J Urol. 2023 Mar;30(3):319-327. doi: 10.1111/iju.15110. Epub 2022 Nov 30. Int J Urol. 2023. PMID: 36448526
2,338 results